Revolutionizing ADHD Treatment: The Power of Eye-Tracking AI
In a groundbreaking move, HarmonEyes, the AI-driven eye-tracking pioneer, has acquired iFocus Health, a game-changer in ADHD care. This acquisition brings a unique, clinically-proven tool to the table, one that uses eye movement to assess medication effectiveness in real-time. But here's where it gets controversial: traditional ADHD treatment relies heavily on subjective self-reports and observations, leaving room for uncertainty. iFocus Health aims to change that, offering an objective, data-driven approach.
The iFocus platform tackles a critical issue in ADHD management: the absence of reliable, immediate biomarkers to gauge treatment success. Typically, medication adjustments are based on patient reports, checklists, and provider observations - methods that often leave patients and their families in the dark. iFocus Health introduces a paradigm shift by tracking subtle eye movements during everyday tasks like reading, providing clinicians with actionable, objective data. This personalized approach transforms ADHD treatment, making it less about guesswork and more about measurable progress.
"ADHD isn't just about distraction; it's about underperformance in a world that demands focus. And this is the part most people miss - we've lacked effective tools to measure treatment efficacy in real-time," says Adi Diner, CEO and co-founder of iFocus Health. "With HarmonEyes, we're taking a giant leap forward, combining our missions with a powerful technology engine to bring this capability to millions."
Now rebranded as HarmonEyes Focus, this technology is a key component of HarmonEyes' mission to use eye movement as a window into human performance. HarmonEyes' AI models provide real-time insights into cognitive, emotional, and physical states. iFocus adds a crucial layer, enabling the measurement and improvement of individual responses to ADHD treatment. Whether in healthcare, education, or daily life, the goal is to understand the brain's dynamics and help individuals perform at their peak.
According to the CDC, millions of children and adults in the U.S. have been diagnosed with ADHD. Yet, most medication management still relies on self-reporting and generic checklists. The tools for assessing treatment efficacy have remained stagnant for decades. HarmonEyes Focus aims to change this. It offers clinicians a data-driven, real-time view of medication effectiveness, helping them fine-tune dosages and treatment plans with confidence, not guesswork.
"This acquisition is a strategic move towards building the world's first foundational model for eye-tracking to understand the human state," says Adam Gross, CEO and co-founder of HarmonEyes. "iFocus brings a proven, relevant use case that aligns perfectly with our vision. By combining their objective treatment measurement approach with our real-time eye-tracking AI platform, we're unlocking new ways to support focus, readiness, and mental performance across various domains."
The acquisition of iFocus by HarmonEyes opens doors to bring objectivity into high-impact human decision-making. In the future, this platform could be adapted to support other neurodivergent conditions, optimize performance in classrooms and workplaces, and enhance focus and recovery in clinical settings.
For more information on HarmonEyes, its cutting-edge eye-tracking solutions, and other company updates, visit www.harmoneyes.com.
About HarmonEyes:
HarmonEyes is the world's first open, AI-powered eye-tracking platform that predicts and identifies cognitive, emotional, and physical states based solely on eye movements. Compatible with any camera-based device, HarmonEyes offers a comprehensive solution for eye-tracking data analysis, model development, and scalable solution deployment with Theia™ SDK. Backed by decades of eye-tracking expertise and built on the largest validated eye-tracking database, HarmonEyes is trusted by leading organizations in technology, aviation, healthcare, and elite performance in military and sports. Learn more and request a demo at www.harmoneyes.com.
Media Contacts:
Lightspeed PR
[email protected]
